Accueil du site > Revue de presse > Sources d’information > Médical > AIDSMeds.com
AIDSMeds.com
http://www.aidsmeds.com/news/TopStories.htm
Fil d’information de Reuters Health (en anglais) sur l’actualité thérapeutique du VIH.
-
Rates of Drug-Resistant Staph Increasing in People With HIV
New cases of skin infections caused by drug-resistant staph have become more common in recent years in some people living with HIV, according to a study published in the November issue of HIV Medicine.
-
Selzentry Receives Full FDA Approval
Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer's HIV entry inhibitor, Selzentry (maraviroc), for treatment-experienced patients.
-
Bavituximab: A New Strategy for Fighting Viruses
Bavituximab is a new type of antiviral drug that could work against a number of different types of viral infections—possibly even against HIV itself. According to a study published in the November 23 issue of Nature Medicine and reported by Science Daily, Bavituximab has shown promise in animal (...)
-
Once-Daily Intelence Could Work as First-line Treatment
Intelence (etravirine) may be potent enough for once-daily use in people who are new to antiretroviral (ARV) therapy, according to a study presented at the Ninth Congress on Drug Therapy in HIV Infection in Glasgow and reported by aidsmap.com. Intelence is currently approved for twice-a-day use (...)
-
Risks Remain for Late Treatment Takers
HIV-positive people who don't start antiretroviral (ARV) therapy until their immune systems are seriously compromised have little difficulty reducing their viral loads, but they still face an increased risk of an AIDS-related disease and death for up to two years after treatment is commenced, (...)
-
Cancer Risk Doubled in People With HIV
Rates of cancers of the lungs, liver, head and neck in people living with HIV are twice that of their HIV-negative counterparts, according to a new study presented at the seventh annual American Association for Cancer Research International Conference on Frontiers in Cancer Research and (...)
-
Shutting Down an HIV Protein May Lead to Brain-Protecting Drugs
Researchers have discovered a new way that an HIV protein called Tat harms the brain, according to a study published in the online journal PLoS One and reported by Science Daily. The authors were able to block this damage in the laboratory, potentially opening up new avenues for developing the (...)
-
Second-line Treatment Fails Twice as Often as First-line
A person's first antiretroviral (ARV) drug regimen remains the best opportunity he or she has in terms of keeping viral load undetectable, suggests a study presented at the Ninth International Congress on Drug Therapy in HIV Infection in Glasgow. According to AIDSmap's review of the study, (...)
-
Small Study Fingers 'Silent' Heart Disease in HIV-Positive Men
A team of French researchers recommends regular cardiovascular disease checkups for people on antiretroviral (ARV) therapy, even if they don't have a history or obvious symptoms of heart problems. This suggestion stems from new study results, published in the November 30 issue of AIDS, (...)
-
Treatment Interruptions May Still Have a Future
Temporarily stopping antiretroviral (ARV) therapy may turn out to be safe and advantageous in some circumstances, according to two studies presented at the Ninth International Congress on Drug Therapy in HIV Infection held in Glasgow and reported by (...)